Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4872608
Max Phase: Preclinical
Molecular Formula: C55H74F15N13O16
Molecular Weight: 888.13
Molecule Type: Unknown
Associated Items:
ID: ALA4872608
Max Phase: Preclinical
Molecular Formula: C55H74F15N13O16
Molecular Weight: 888.13
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(=O)N[C@@H](CCCN)C(=O)NC(=O)[C@H](C)NC(=O)[C@@H](CCCNC(=N)N)NCCN1CCN(CCCC2CCN(CC(=O)N3c4ccccc4NC(=O)c4ccccc43)CC2)CC1.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F
Standard InChI: InChI=1S/C45H69N13O6.5C2HF3O2/c1-31(41(61)54-44(64)37(13-7-19-46)52-32(2)59)51-43(63)36(14-8-20-50-45(47)48)49-21-25-56-28-26-55(27-29-56)22-9-10-33-17-23-57(24-18-33)30-40(60)58-38-15-5-3-11-34(38)42(62)53-35-12-4-6-16-39(35)58;5*3-2(4,5)1(6)7/h3-6,11-12,15-16,31,33,36-37,49H,7-10,13-14,17-30,46H2,1-2H3,(H,51,63)(H,52,59)(H,53,62)(H4,47,48,50)(H,54,61,64);5*(H,6,7)/t31-,36+,37-;;;;;/m0...../s1
Standard InChI Key: FTHDLNPSKQHHNE-URNDRGBWSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 888.13 | Molecular Weight (Monoisotopic): 887.5494 | AlogP: 0.64 | #Rotatable Bonds: 22 |
Polar Surface Area: 263.45 | Molecular Species: BASE | HBA: 12 | HBD: 9 |
#RO5 Violations: 3 | HBA (Lipinski): 19 | HBD (Lipinski): 11 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 11.38 | CX Basic pKa: 11.98 | CX LogP: -1.67 | CX LogD: -6.85 |
Aromatic Rings: 2 | Heavy Atoms: 64 | QED Weighted: 0.04 | Np Likeness Score: -0.31 |
1. Weinhart CG, Wifling D, Schmidt MF, Neu E, Höring C, Clark T, Gmeiner P, Keller M.. (2021) Dibenzodiazepinone-type muscarinic receptor antagonists conjugated to basic peptides: Impact of the linker moiety and unnatural amino acids on M2R selectivity., 213 [PMID:33571911] [10.1016/j.ejmech.2021.113159] |
Source(1):